JPMorgan’s top stock guru says stay underweight equities, investors are too optimistic about economy
Marko Kolanovic said investors are ignoring the risks that could still lead to a recession.
College is more expensive than ever. Here’s how families are paying the tab
To cover the rising cost of college, most families have to rely on a combination of resources, including loans, to make it work.
Philadelphia Fed President Patrick Harker suggests interest rate hikes are at an end
A voter this year on the rate-setting FOMC, Harker noted progress in the fight against inflation and confidence in the economy.
Mike Pence qualifies for first GOP presidential debate, joining Trump, DeSantis, Haley and others
Pence joins Ron DeSantis, Nikki Haley, Chris Christie, Tim Scott and other qualifiers — but frontrunner Donald Trump has signaled he’ll skip the debate.
Novavax posts surprise quarterly profit as company prepares to launch new Covid vaccine
Novavax is working to strengthen its financial position after it raised doubts about its ability to stay in business earlier this year.
Billionaire Charlie Ergen merging Dish and EchoStar to expand mobile and satellite telecom empire
Dish — which owns Boost Mobile, Ting, Republic Wireless and Gen Mobile — is looking to expand beyond satellite TV into the mobile telecommunications market.
Truist upgrades DraftKings, says sports betting stock has clear path to profitability
Truist upgraded shares to buy from hold following the company’s better-than-expected second-quarter results.
BMO names this software stock as a top pick, citing A.I. tailwinds
Analyst Keith Bachman named Adobe to his top picks list, citing potential upsides from generative artificial intelligence and a reasonable valuation.
Home improvement retailers downgraded by research firm Telsey, citing end of post-Covid boom
The firm downgraded both shares to market perform from outperform, citing a weakening housing market.
Goldman says this little-known biotech stock could more than double
The firm initiated a buy rating on shares, citing its promising fatty acid synthase inhibitor technology.
